Skip to main content
    V

    Vanda Pharmaceuticals Inc (VNDA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.81
    +0.00 (+0.00%)

    Market Cap: $230.39M

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Vanda Pharmaceuticals Inc (VNDA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Vanda Pharmaceuticals (VNDA) has a market cap of $230.39M and an enterprise value of $170.80M. It kept -119.87% of revenue as net income over the last 12 months. It holds $59.59M more cash than debt, 25.86% of its market cap.

    Total Valuation

    Enterprise value is 25.86% below the market cap, as cash exceeds debt.

    Market Cap$230.39M
    Enterprise Value$170.80M
    Latest price (Nov 17, 2026)$3.81

    Key Dates

    The next earnings report is expected on Feb 9, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 9, 2027 (expected)
    Last Earnings DateOct 28, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.40% in the quarter ended Sep 30, 2026 and grew 1.87% a year over 2 years.

    Shares Outstanding60.47M
    Shares Change (YoY)+2.32%
    Shares Change (QoQ)+0.40%
    Share Count Growth (2Y CAGR)+1.87%

    Valuation Ratios

    Sales and book value multiples are 1.0x and 1.2x. Its year-end P/S ranged from 1.3x to 7.0x from 2016 to 2025.

    P/S Ratio1.0x
    Forward P/S1.0x
    P/B Ratio1.2x
    P/TBV Ratio2.6x

    Valuation history and multiples

    Price Statistics

    The stock is down 12.41% over 52 weeks and trades 14.00% below its 50-day average.

    Beta (1Y)1.05
    52-Week Change-12.41%
    1-Month Change-6.85%
    3-Month Change-31.60%
    6-Month Change-36.39%
    5-Year Change-77.86%
    10-Year Change-74.48%
    Total Return (1Y)-12.41%
    Total Return (3Y CAGR)+2.38%
    Total Return (5Y CAGR)-26.07%
    Return vs SPY (1Y)-40.34%
    Max Drawdown (1Y)-62.45%
    Max Drawdown (3Y)-62.45%
    Sharpe Ratio (1Y)-0.46
    Correlation with SPY (1Y)0.20
    50-Day Average$4.43
    200-Day Average$5.98
    52-Week Range$3.57 to $9.94
    RSI (14 Days)40.6
    Average Volume (20 Days)1.31M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.54x current liabilities, and total debt is 0.01x shareholder equity.

    Current Ratio1.54x
    Quick Ratio1.53x
    Debt / Equity0.01x

    Returns and Efficiency

    Return on invested capital is -84.67% over the last 12 months, against a 5-year average of -41.85%.

    Return on Equity (ROE)-137.51%
    Return on Assets (ROA)-71.88%
    Return on Invested Capital (ROIC)-84.67%
    Return on Capital Employed (ROCE)-75.30%
    ROE (5Y Average)-12.54%
    ROA (5Y Average)-8.20%
    ROIC (5Y Average)-41.85%
    Asset Turnover0.47x
    Inventory Turnover9.17x
    Receivables Turnover3.82x
    Cash Conversion Cycle-1485 days

    Scores

    VNDA has an Altman Z-Score of -1.79, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-1.79
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $229.28M over the last 12 months is up 8.11% from the 12 months before.

    Revenue$229.28M
    Revenue Growth (YoY)+8.11%
    Gross Profit$214.57M
    Operating Income-$177.91M
    Pretax Income-$171.20M
    Net Income-$274.83M
    EBITDA-$155.00M
    EBIT-$171.20M
    Reported EPS (TTM)-$4.62

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 52.27% of the $382.33M in total assets.

    Cash and Equivalents$61.93M
    Total Debt$2.35M
    Net Cash$59.59M
    Net Cash Per Share$0.99
    Working Capital$83.49M
    Shareholder Equity$199.86M
    Book Value Per Share$3.31
    Tangible Book Value$88.73M
    Tangible Book Per Share$1.47
    Total Assets$382.33M
    Total Liabilities$182.47M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $824.00K of capital spending, operating cash flow left -$139.96M of free cash flow.

    Operating Cash Flow-$139.14M
    Capital Expenditures$824.00K
    Free Cash Flow-$139.96M
    FCF Per Share-$2.31
    Depreciation and Amortization$16.19M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -77.59%, against a 5-year average of -15.89%.

    Gross Margin93.59%
    Operating Margin-77.59%
    Pretax Margin-74.67%
    Net Margin-119.87%
    EBITDA Margin-67.61%
    EBIT Margin-74.67%
    FCF Margin-61.05%
    Gross Margin (5Y Average)92.30%
    Operating Margin (5Y Average)-15.89%
    Net Margin (5Y Average)-19.08%

    Growth

    Revenue fell 5.29% a year over 3 years.

    Revenue Growth (3Y CAGR)-5.29%
    Revenue Growth (5Y CAGR)-2.73%
    Book Value Per Share Growth (2Y CAGR)-23.55%
    Tangible Book Per Share Growth (2Y CAGR)-30.51%

    Revenue and profit by year

    Dividends and Yields

    VNDA does not pay a dividend. Its free cash flow yield is -60.76%.

    FCF Yield-60.76%
    Shareholder Yield0.00%

    Peer Position

    Against 6 similar companies, VNDA has the lowest P/S.

    P/S Ratio1.0x vs 11.4x median
    Revenue Growth (Trailing 4 Quarters, YoY)+8.11% vs -97.79% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 20.97% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+20.97%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About VNDA

    What is VNDA's market cap?

    Vanda Pharmaceuticals has a market cap of $230.39M. Its enterprise value, which adds debt and subtracts cash, is $170.80M.

    How many shares of VNDA are outstanding?

    Vanda Pharmaceuticals has 60.47M shares outstanding. The count is up 2.32% from a year earlier.

    Does VNDA pay a dividend?

    No. Vanda Pharmaceuticals does not pay a dividend.

    How much debt does VNDA have?

    Vanda Pharmaceuticals has $2.35M of total debt and $61.93M of cash and equivalents, a net cash position of $59.59M.